AstraZeneca to Acquire Fusion Pharmaceuticals for Up to $2.4 Billion

Fusion Pharmaceuticals Announces Agreement to be Acquired by AstraZenecaFusion Pharmaceuticals, Inc. announced that it has reached a definitive agreement to be acquired by AstraZeneca. According to the terms of the definitive agreement, AstraZeneca will acquire all outstanding shares of Fusion through a subsidiary at a price of $21 per share in cash, plus a non-transferable contingent value right (CVR) of $3 per share in cash payable upon the achievement of specific regulatory milestones. The upfront cash portion of the transaction is valued at approximately $2 billion, and together with the maximum potential contingent value payment, the total transaction is valued at approximately $2.4 billion. (Source: Jiemian)Original Link